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CXCR4 (also termed fusin, LESTR, or HUMSTR) is a member of the G-protein-coupled chemokine receptor
family with seven membrane-spanning domains. CXCR4 acts as a coreceptor for syncytium-inducing human
immunodeficiency virus type 1 (HIV-1) strains, conferring entry into CD41 cells. We show here that a novel
mouse monoclonal antibody (12G5) that recognizes CXCR4 blocked cell-to-cell fusion and cell free-virus
infection of CXCR41 CD41 RD rhabdomyosarcoma cells by seven HIV-1 and HIV-2 strains that had various
cell tropisms for different CD41 human cell types. Yet the majority of the members of the same virus panel
resisted 12G5 inhibition on T-cell lines. When inhibition was observed on these cell types, it was both cell type
and virus strain dependent. In at least one situation, 12G5 failed to block LAI infection of cells expressing
CXCR4 as the only available coreceptor. Our observations suggest that CXCR4 could be processed or
presented differently depending on the cell type, allowing some strains to evade 12G5 inhibition. Alternatively,
since several of the viruses could infect certain CXCR42 CD41 cell lines, it is conceivable that alternative
coreceptors are active, enabling individual HIV strains to choose between compatible coreceptors during entry
into cells. Moreover, the strain dependency of 12G5 inhibition implies that the interaction of different HIVs
with CXCR4 varies.
Human immunodeficiency virus (HIV) enters cells by at-
taching to cell surface CD4 before interacting with a corecep-
tor that triggers fusion of viral and cellular membranes.
CXCR4 (also called fusin, LESTR, or HUMSTR) (14, 16, 17,
19, 26) is a member of the seven-transmembrane-domain, G-
protein-coupled receptor family and has been shown to act as
a coreceptor for syncytium-inducing, T-cell-line-adapted HIV
type 1 (HIV-1) strains (15). Other chemokine receptors can
also be used as coreceptors by HIV-1 strains. CCR5 (30) acts
as a coreceptor for non-syncytium-inducing (NSI) macro-
phage-tropic strains (1, 10, 12), while some primary strains can
also use CCR3 (5, 11, 32). Other chemokine receptors, e.g.,
CCR2b, have been shown to be functional at least for cell-to-
cell fusion (11).
Chemokines are small (8- to 10-kDa) proteins and are the
natural ligands for chemokine receptors. For instance, the
chemokines RANTES, MIP-1a, and MIP-1b all interact with
CCR5 (30), and stroma-derived factor (SDF) has recently been
shown to be a ligand for CXCR4 (2, 27). These chemokines
block infection of HIV-1 strains that use CCR5 and CXCR4,
respectively. For example, RANTES, MIP-1a, and MIP-1b
inhibit infection of CCR5-expressing peripheral blood
mononuclear cells (PBMCs) by NSI macrophage-tropic vi-
ruses, while SDF has been shown to block infection of
CXCR41 HeLa/CD4 cells by the T-cell-line-adapted HIV-1
strain LAI. Here, we show that a monoclonal antibody (MAb)
specific for CXCR4 also blocks HIV infection of CXCR41
cells, although inhibition is cell type and virus strain specific.
12G5 is a recently described mouse MAb that specifically
recognizes CXCR4 but not other members of the chemokine
receptor family, including CCR1-5 and interleukin-8 receptors
a and b (13). As far as we know, 12G5 is the only MAb
available that recognizes the HIV coreceptor CXCR4. Figure
1A shows the levels of cell surface CXCR4 expression deter-
mined by flow cytometry after 12G5 staining of the CD41
T-cell lines MOLT-4 and C8166, the CD4-transfected human
rhabdomyosarcoma cell line RD, and the human glioma cell
line U87 as well as primary macrophages purified by adherence
to plastic and cultured for 1 or 5 days (22, 31). Flow cytometry
was carried out as previously described (21). HIV infectivity of
macrophages or PBMCs is routinely estimated by infecting
cells that have been cultured for 5 days after purification from
blood or buffy coats. We were therefore particularly interested
in assessing CXCR4 expression for cultures of this age. Prior to
staining with 12G5, macrophages and PBMCs were preincu-
bated with 5% heat-aggregated hyperimmune gamma globulin
(Miles Cutler) on ice for 30 min to block any nonspecific
binding to Fc receptors. Figures 1B and C show the results of
reverse transcription-PCR (RT-PCR) and Northern blot anal-
yses, respectively, of RNA prepared from the same cell types as
shown in Fig. 1A. RNA for RT-PCR was prepared with RNA-
zol. cDNA was then prepared from 5 mg of RNA by using the
Stratagene RT-PCR kit. One-twentieth of the cDNA prepared
was included in the PCR reactions. PCR for CXCR4 used the
primers 59-TAG ATA TCT TAC CAT GGA GGG GAT
CAG-39 and 59-TAG CGG CGC TTA GTG GAG TGA AAA
CTT G-39, corresponding to the positive and negative strands,
respectively, and amplifying a 1,044-bp fragment. The positive-
strand primer incorporated a 59 tail which encoded an EcoRV
site, and the minus strand incorporated a 39 tail encoding a
* Corresponding author. Mailing address: Virology Laboratory,
Chester Beatty Laboratories, The Institute of Cancer Research, 237
Fulham Rd., London SW3 6JB, United Kingdom.
1692
 o
n
 M
arch 2, 2014 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
NotI site. Conditions for CXCR4 amplification were 30 cycles
of 958C for 30 s, 508C for 30 s, and 728C for 1 min. Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) sequences were
amplified by using the positive-strand primers 59-TGG ATA
TTG CCA TCA ATG ACC-39 and the negative-strand primer
59-GAT GGC ATG GAC TGT GGT CAT G-39. Conditions
for the PCR were 40 cycles of 958C for 30 s, 658C for 1 min, and
728C for 30 s. Control PCR analysis of the RNA preparations
was consistently negative for both CXCR4 and GAPDH DNA.
mRNA for Northern blot analysis was prepared from 106 to
107 cells (Pharmacia Quickprep Micro mRNA isolation sys-
tem), and 1 mg was fractionated on a 1.2% agarose–formalde-
hyde gel. RNA was transferred overnight onto a Genescreen
Plus membrane (NEN) with 103 SSPE (13 SSPE is 0.18 M
NaCl, 10 mM NaH2PO4, and 1 mM EDTA) and then baked at
808C for 2 h. 32P-labelled CXCR4 and GAPDH double-
stranded probes were prepared by random priming (Amer-
sham) and hybridized to the membrane in Quickhyb solution
(Stratagene) for 1 h at 658C. The membrane was washed twice
for 15 min at room temperature in 23 SSC (13 SSC is 0.15 M
NaCl plus 0.015 M sodium citrate)–0.1% sodium dodecyl sul-
fate and once for 30 min at 658C in 0.13 SSC–0.1% sodium
dodecyl sulfate. The blot was then exposed at 2708C for 1
week. Cell lines used in Fig. 1 and throughout this study,
including RD/CD4, U87/CD4, HeLa/CD4, SCL/CD4, Daudi,
and CD41 T-cell lines C8166, MOLT-4, MT-2, SSCEM, and
Sup T1, have all been described previously (4, 6–8, 18, 20, 23,
24). WI-38/t cells are simian virus 40-transformed counterparts
of the WI-38 human diploid cell line (28).
Figure 1 shows that 12G5 detection of cell surface CXCR4
by flow cytometry correlated well with CXCR4 mRNA detec-
tion by RT-PCR or by Northern blotting. Both CD41 T-cell
lines (MOLT-4 and C8166) as well as RD cells were highly
positive for CXCR4 cell surface expression as well as for
CXCR4 mRNA expression by RT-PCR and by Northern blot-
ting. Neither CXCR4 protein nor mRNA could be detected in
U87 cells. Primary macrophages were highly positive for cell
surface CXCR4 expression after 1 day of culture; however,
expression had dropped substantially by 5 days. Northern blot
and RT-PCR analyses of 5-day-old primary macrophages were
positive for CXCR4 mRNA but at a lower level than cell lines
MOLT-4, C8166, and RD.
Table 1 summarizes the data shown in Fig. 1 and includes a
survey of other cell types, including Daudi (a B-cell line),
HeLa/CD4, and the CD41 T-cell lines H9 and MT-2 as well as
phytohemagglutinin- and interleukin-2-stimulated PBMCs cul-
tured for 5 days as described previously (32). All of these cell
types stained positive for CXCR4 cell surface expression. Ex-
pression of CXCR4 by cell lines ranged from 35.5% for HeLa/
FIG. 1. Detection of CXCR4 cell surface glycoprotein and mRNA. (A) Flu-
orescence-activated cell sorter analysis of cell surface CXCR4 expression by
12G5 staining on MOLT-4, C8166, U87/CD4, and RD/CD4 cells as well as on
primary human macrophages (MAC) cultured for 1 and 5 days. (B and C)
CXCR4 mRNA detection by Northern blotting (B) and by RT-PCR (C) on the
same cells as in panel A, except two batches of primary macrophages (cultured
for 5 days) were included for each method.
TABLE 1. Correlation of CXCR4 expression and infection
by T-cell-line-passaged HIV-1
Cell type Source
Level of CXCR4
expression
determined by:
Infection by
HIV-1 LAI
mRNAa 12G5b
RD/CD4 Rhabdomyosarcoma 11 93.3 1
HeLa/CD4 Cervical carcinoma 11 35.5 1
U87/CD4 Glioma 2 ,2 2
SCL/CD4 Skin 2 ,2 2
WI-38t/CD4 Lung 2 ,2 2
Daudi/CD4 B cell 11 88.4 1
C8166 T cell 11 72.0 1
MOLT-4 T cell 11 89.5 1
Sup T1 T cell NTc 81.5 1
H9 T cell NT 51.4 1
MT-2 T cell NT 99.0 1
PBMCd 11 27.8 1
Macrophaged 1 5.2 (2)e
a CXCR4 mRNA was measured by RT-PCR. 2, no CXCR4 expressed; 1,
weak CXCR4 expression; 11, high-level CXCR4 expression.
b Values are percentages of cells expressing CXCR4 as determined by fluo-
rescence-activated cell sorter analysis of 12G5 staining.
c NT, not tested.
d CXCR4 expression was estimated after 5 days of culturing PBMCs or mac-
rophages. The percentages of 12G5-positive cells are averages derived from
staining 10 batches of PBMCs and 3 batches of macrophages, each from different
donors.
e (2), inefficient infection only.
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CD4 to .99% for MT-2 cells. Other human cell lines, such as
SCL skin and WI-38/t lung cells, were negative for CXCR4
expression by 12G5 staining and for CXCR4 mRNA, like U87
glioma cells. Thus, CXCR4 is expressed widely on human
hematopoietic cell types and on some nonlymphoid cell types
but is absent from the surfaces of human U87 glioma, SCL
skin, and WI-38/t lung cells and is only weakly expressed on
5-day-old macrophages derived from blood monocytes. This
pattern of CXCR4 expression correlates well with the sensitiv-
ity of these CD41 cell types to infection by T-cell-line-passaged
HIV-1 strains such as LAI and RF (Tables 1 and 2) (4, 6).
However, HIV-2 strains (e.g., ROD) and some HIV-1 strains
(e.g., the GUN-1 variant [GUN-1var]) show a broader tropism
and can infect several CXCR42 cell types (e.g., U87/CD4) (6,
20, 22, 31, 33).
We tested whether 12G5 could inhibit cell-to-cell fusion
induced by a panel of HIV-1 and HIV-2 strains. The HIV-1
and HIV-2 strains tested were chosen because they show dis-
tinct tropisms for various CD41 cell types (summarized in
Table 2), but all infect CD41 T-cell lines as well as HeLa/CD4
and RD/CD4 cells. The wild-type GUN-1 strain of HIV-1
(GUN-1wt) is dual tropic and, unlike LAI and RF, efficiently
infects primary macrophages as well as CD41 T-cell lines (22,
31). A single amino acid change in the V3 loop of GUN-1var
results in the loss of macrophage tropism but confers efficient
infection of CXCR42 CD41 U87 glioma cells (22, 33). Also,
the HIV-2 strains used have a broader tropism for CD41
human and nonhuman cell types (6, 20), several of which do
not express CXCR4. HIV-2 ROD/B is a variant of the proto-
type ROD strain (ROD/A) that can infect certain CD42 hu-
man cell types (7) with CXCR4 alone as a receptor (13) yet still
retains the broad, CD4-dependent tropism characteristic of
most T-cell-line-passaged HIV-2 isolates (reference 20 and
unpublished observations). Uninfected target cells (e.g., RD/
CD4 cells) were treated for 30 min with 12G5 dilutions before
addition of an equal number of H9 cells chronically infected
with an appropriate HIV-1 or HIV-2 strain. Cocultivations
were incubated at 378C overnight before syncytium formation
was estimated as described before (6, 7, 20). Table 3 shows that
12G5 inhibited induction of cell-to-cell fusion of CXCR41
RD/CD4 cells by all HIV-1 and HIV-2 strains tested. Thus,
each of the seven HIV isolates tested uses CXCR4 as a core-
ceptor on RD/CD4 cells during fusion.
We next tested whether 12G5 could inhibit HIV-1- and
HIV-2-induced cell-to-cell fusion of CXCR41 CD41 T-cell
lines as well as other CD41 cell types (either CXCR41 or
CXCR42). Table 3 shows that 12G5 failed to inhibit cell-to-
cell induction of fusion by any of the seven viruses on the T-cell
lines MOLT-4, Sup T1, and MT-2, although a slight but con-
sistent reduction in syncytium formation was seen for the
HIV-1 GUN-1 strains on MOLT-4 and Sup T1 cells with the
highest dose of 12G5 (20 mg/ml). In contrast, fusion of C8166
and SSCEM T cells as well as HeLa/CD4 cells by both HIV-1
GUN-1wt and Gun-1var was blocked by 12G5 even though
fusion by the other strains on these cell types was resistant.
Likewise, HIV-2 CBL-23 was blocked for fusion on C8166 and
HeLa/CD4 yet resisted 12G5 inhibition on SSCEM. 12G5 in-
hibition of HIV-1- and HIV-2-induced cell fusion of cell types
other than RD/CD4 is therefore complex, being cell type as
well as virus strain dependent. Clearly, some strains are effi-
ciently inhibited while others are resistant.
At this point we had tested 12G5 inhibition of HIV-1- and
HIV-2-induced cell fusion. We next tested whether infection
by cell-free virus was also inhibited. RD/CD4 or HeLa/CD4
were seeded at 2 3 104 cells per well in 24-well trays 2 days
before infection. Cells were treated for 30 min with 100 ml of
appropriate 12G5 antibody dilutions. Virus supernatant (100
ml) containing between 50 and 100 focus-forming units was
added, and the cultures were incubated for a further 90 min.
Inocula were then removed, and cells were washed twice be-
fore addition of 1 ml of growth medium and incubation for 4
days. Foci of infection were detected by immunostaining as
previously described (7). Figures 2A and B show that the
pattern of 12G5 inhibition of infectivity for RD/CD4 cells and
HeLa/CD4 cells exactly followed that observed for inhibition
of cell fusion. The infectivity of all strains tested on RD/CD4
cells was inhibited by 12G5. However, on HeLa/CD4 cells,
GUN-1wt was blocked by 12G5 whereas only slight inhibition
of the LAI and RF strains was observed.
The simplest explanation for these results is that certain
HIV strains can use coreceptors other than CXCR4 on some
cell types (and particularly on CD41 T-cell lines) and are
therefore not substantially inhibited by 12G5. For the T-cell-
line-adapted strains used in this study, CXCR4 must be the
only coreceptor choice on CXCR41 CD41 RD cells, so the
anti-CXCR4 MAb 12G5 inhibits infection. On most CXCR41
CD41 T-cell lines, 12G5 failed to inhibit HIV-1 and HIV-2
TABLE 2. Summary of expression of CXCR4 and susceptibility
to infection by HIV-1 and HIV-2 strains
CD41 cell line
or type used
Level of
CXCR4
expres-
siona
Infection byb:
HIV-1 strain HIV-2 strain
LAI RF Gun-1wt Gun-1var ROD CBL-23
RD/CD4 11 1 1 1 1 1 1
HeLa/CD4 11 1 1 1 1 1 1
U87/CD4 2 2 2 2 1 1 1
WI-38/t/CD4 2 2 2 2 1 1 NTc
CD41 T-cell lines 11 1 1 1 1 1 1
PBMC 11 1 1 1 1 1 1
Macrophage 1 (2)d (2) 1 (2) 1 NT
a 2, no CXCR4 expression; 1, low-level CXCR4 expression; 11, high-level
CXCR4 expression.
b 2, not susceptible; 1, susceptible.
c NT, not tested.
d (2), inefficient infection only.
TABLE 3. Inhibition of HIV-1- and HIV-2-induced syncytium
formation on CD41 cell lines by 12G5
CD41 cell line
Titer of 12G5 syncytium-inhibiting activitya
HIV-1 strain HIV-2 strain
LAI RF Gun-1wt Gun-1var ROD A/B CBL-23
RD/CD4 2.5 2.5 1.25 0.625 5 2.5
HeLa/CD4 .20b .20b 5 5 .20 5
C8166 .20 .20 2.5 2.5 .20 2.5
MOLT 4 .20 .20 .20b .20b .20 .20
Sup T1 .20 .20 .20b .20 .20 .20
MT-2 .20 .20 .20 .20 .20 .20
U87/CD4/CXCR4 .20
a Antibody titers were estimated as the highest concentration of 12G5 (mg/ml)
that inhibited .95% syncytium formation; i.e., .20 means there was no inhibi-
tion by 12G5 up to a concentration of 20 mg/ml, whereas 1.25 means that 12G5
blocked .95% of syncytium formation at 1.25 mg/ml but lower concentrations
inhibited less or not at all. Unless otherwise noted, the titers shown refer to
.95% syncytium inhibition.
b Consistent reduction of up to 50% syncytium formation at 20 mg/ml was seen.
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fusion, suggesting the presence of alternative coreceptors. This
interpretation is supported by the observation that certain
HIV-1 (GUN-1wt and Gun-1var) and HIV-2 strains can infect
at least some CXCR42 CD41 cell types (Table 2) and there-
fore must use alternative coreceptors for entry into these cells.
Thus, as reported already by Choe et al. (5) and Doranz et al.
(11), at least some HIV strains can choose between compatible
alternative coreceptors for CD4-dependent entry. Further-
more, we have recently shown that several primary dual-tropic
HIV-1 isolates (as well as GUN-1wt) infected cat CCC cells
expressing human CD4 as long as either CXCR4 or CCR5 was
present, while a subset of the primary strains could use CCR3,
CCR5, or CXCR4 (32). Yet, LAI- and RF-induced fusion of
C8166, as well as GUN-1wt-induced fusion of MOLT-4 cells,
which are resistant to 12G5 inhibition, also resisted inhibition
by a combination of 12G5 (20 mg/ml) and RANTES (200
ng/ml). RANTES binds to a number of CC chemokine recep-
tors (3, 25, 29, 30), including CCR5, a coreceptor for NSI
macrophage-tropic HIV-1 strains (1, 10, 12, 34) and inhibits
PBMC infection by NSI macrophage-tropic strains (9, 10, 12).
Thus, if alternative coreceptors present on CD41 T-cell lines
are exploited by the virus strains used here, it is unlikely that
they are receptors for RANTES.
Yet, we favor the interpretation that the processing or pre-
sentation of CXCR4 is different on different cell types, en-
abling at least some HIV strains to evade 12G5 inhibition.
Perhaps on some cell types, other cell surface molecules inter-
act with CXCR4, influencing HIV recognition of the corecep-
tor. Indeed, expression of CXCR4 on CD41 U87 cells (10, 13)
confers sensitivity to LAI fusion which is resistant to 12G5
inhibition (Table 3). Thus, at least for this situation, in which
recombinant CXCR4 should be the only coreceptor available
for LAI on U87/CD4 cells, 12G5 fails to block fusion. Further-
more, although 12G5 failed to block LAI infection of HeLa/
CD4 cells, others have shown that the CXCR4 ligand SDF
does block infection (2, 27). Assuming that SDF is specific for
CXCR4, this observation implies that CXCR4 is the only co-
receptor available for LAI on HeLa/CD4 cells. Thus, although
12G5 binds to CXCR4 on both RD/CD4 and HeLa/CD4 cells,
differences in the processing or presentation of CXCR4 must
enable LAI to resist 12G5 inhibition on HeLa/CD4 cells but
not on RD/CD4 cells.
The existence of different forms of CXCR4 presentation on
different cell types may explain the cell-type-dependent inhi-
bition of HIV strains shown here but does not resolve why
inhibition on some cell types (e.g., C8166 and HeLa/CD4) was
also virus strain dependent. It is thus likely that different
strains interact differently with CXCR4 to trigger fusion. Al-
though the natures of the different interactions are currently
unknown, this hypothesis is supported by our recent observa-
tion that deletions at the N terminus of CXCR4 have different
effects depending on the HIV strain tested (27a).
In summary, we have shown that there is inhibition of HIV-
induced infection and cell-to-cell fusion by a novel MAb
(12G5) to CXCR4, the coreceptor for T-cell-line-adapted HIV
strains. 12G5 inhibition was cell type and virus strain depen-
dent. Variations in processing or presentation of CXCR4 or
expression of alternative coreceptors meant that 12G5 failed to
block most HIV-1 and HIV-2 strains on CD41 T-cell lines.
These results indicate that the designing of therapeutic mole-
cules to intervene in HIV and coreceptor interaction will not
be straightforward and suggest that resistant escape mutants
will emerge.
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